SCHEMBL21145359

SCHEMBL21145359

CC1(C)OB(c2ccc3oc([C@@]4(F)CCCN(C(=O)O)C4)nc3c2)OC1(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 8/20 0.39
ROCK1 Q13464 1/20 0.35
IDO1 P14902 1/20 0.33
TDO2 P48775 1/20 0.33
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
F2 P00734 1/20 0.31
F11 P03951 1/20 0.31
PRSS1 P07477 1/20 0.31
PRSS2 P07478 1/20 0.31
PRSS3 P35030 1/20 0.31
PROKR1 Q8TCW9 1/20 0.31
CNR2 P34972 1/20 0.30
BACE1 P56817 1/20 0.30
BACE2 Q9Y5Z0 1/20 0.30
DPP4 P27487 1/20 0.30
DPP8 Q6V1X1 1/20 0.30
DPP7 Q9UHL4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21145361 1.00 USP30 (0.39) USP30ROCK1IDO1TDO2NPC1
SCHEMBL20028692 0.87 USP30 (0.41) USP30BACE1BACE2
SCHEMBL20028693 0.87 USP30 (0.41) USP30BACE1BACE2
SCHEMBL21167236 0.84 USP30 (0.34) USP30ROCK1NPC1RAB9ABACE1
SCHEMBL21145396 0.81 USP30 (0.43) USP30NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL21145398 0.81 USP30 (0.43) USP30NPC1RAB9AHPGDSMN1; SMN2
SCHEMBL21145378 0.74 USP30 (0.55) USP30NPC1RAB9AHPGDPROKR1
SCHEMBL21145376 0.74 USP30 (0.55) USP30NPC1RAB9AHPGDPROKR1
SCHEMBL19385142 0.73 SCD5 (0.39) USP30NPC1RAB9A
SCHEMBL19385143 0.73 SCD5 (0.39) USP30NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3519397-B1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LTD (GB) 2021-05-19 EP disclosed
US-10927110-B2 Cyano-subtituted heterocycles with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-02-23 US disclosed
US-20190218215-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218215-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 USP30, USP28, USP1 USP30 1/4885ROCK1 3813/4885IDO1 2293/4885
US-10927110-B2 Cyano-subtituted heterocycles with activity as inhibitors of USP30 USP30, USP28, USP1 USP30 1/4885ROCK1 3813/4885IDO1 2293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.